Haleon company profile
Company profile
Haleon has 24,535 employees and is headquartered in Weybridge, United Kingdom.
Haleon develops, manufactures and sells consumer healthcare products across North America, Europe, the Middle East, Africa, Latin America and the Asia Pacific. Its oral health range includes toothpastes, mouthwashes and denture care under Sensodyne, Polident, Parodontax and Biotene, while Centrum and Caltrate cover vitamins, minerals and supplements. Its over-the-counter lines span cold, flu and allergy relief under Theraflu and Flonase, pain relief under Voltaren, Panadol and Advil, and digestive products under TUMS and ENO. A collaboration with Microsoft supports its digital, data and AI work.
In the fiscal year ended December 2025, Haleon reported revenue of GBP 11.0 billion, down 1.8% from the previous year, and net profit of GBP 1.7 billion. The company employed 24,535 people. It is headquartered in Weybridge, United Kingdom, and was founded in 1715. Its shares also trade on the NYSE.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United Kingdom
- Headquarters
- The Heights, KT13 0NY, Weybridge
- Employees
- 24,535
- Chief executive
- Brian McNamara
- Founded
- 1715
- Fiscal year
- January - December
- Listing
- HLN · LSE
- Indices
- FTSE 100
- Currency
- GBp
- ISIN
- GB00BMX86B70
- Website
- haleon.com
Haleon and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| HaleonHLN | United Kingdom | $40.15B | 24,535 | 23.5% | 19.3 |
| Sandoz GroupSDZ | Switzerland | $43.57B | 20,000 | 9.3% | 72.3 |
| Galderma GroupGALD | Switzerland | $51.94B | 7,676 | 19.1% | 64.5 |
| MerckMRK | Germany | $71.52B | 61,949 | 17.0% | 33.9 |
| Swedish Orphan BiovitrumSOBI | Sweden | $16.27B | 2,207 | 30.9% | 25.0 |
| IpsenIPN | France | $14.2B | 5,535 | 27.4% | 25.5 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
